Bergen Carol, Compher Charlene
Penn Nursing, University of Pennsylvania, 420 Guardian Drive, Philadelphia, PA 19104-6096, USA.
J Cardiovasc Nurs. 2006 Jan-Feb;21(1):40-6. doi: 10.1097/00005082-200601000-00009.
Hyperhomocysteinemia has been linked to an increased risk for cardiovascular (CV) disease since 1969. Recent epidemiological and cohort observations continue to confirm this relationship, provided the homocysteine concentration is elevated. This elevation in homocysteine concentration and increased CV disease risk are particularly strong in patients with renal disease. Hyperhomocysteinemia is also related to declining status of vitamins B6 and B12, folate, and in some cases riboflavin. This relationship between vitamins and homocysteine concentration has provided the basis for clinical trials targeting CV risk reduction by vitamin supplementation. This review describes the evidence behind vitamin supplementation as it pertains to homocysteine status and make recommendations for vitamin intake management in patients with hyperhomocysteinemia, including those patients with renal disease.
自1969年以来,高同型半胱氨酸血症就与心血管(CV)疾病风险增加相关联。近期的流行病学和队列观察持续证实了这种关系,前提是同型半胱氨酸浓度升高。在肾病患者中,同型半胱氨酸浓度的这种升高以及心血管疾病风险的增加尤为显著。高同型半胱氨酸血症还与维生素B6、B12、叶酸以及某些情况下核黄素的水平下降有关。维生素与同型半胱氨酸浓度之间的这种关系为通过补充维生素来降低心血管风险的临床试验提供了依据。本综述描述了与同型半胱氨酸状态相关的维生素补充背后的证据,并对高同型半胱氨酸血症患者,包括肾病患者的维生素摄入管理提出建议。